STIM · CIK 1227636
What Neuronetics, Inc. told the SEC could break it.
Neuronetics' sharpest disclosure is supply fragility: it relies on single-source suppliers for some NeuroStar components — with no long-term supply contracts — and on a single manufacturer to assemble the system's mobile console and patient-positioning unit, so one disruption could halt production. The register then widens to its changed business model: after acquiring Greenbrook, clinic revenue jumped to 59% of U.S. revenue from 6%, making it directly responsible for operating leased treatment centers, while its results still hinge on third-party TMS reimbursement from federal programs, commercial payors and government-managed systems like Japan's, all under FDA medical-device regulation.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Sole-source dependency
- single-source component suppliers and a single assembler for the NeuroStar system (no long-term contracts)high
Neuronetics relies on single-source suppliers for some NeuroStar components — with no long-term supply contracts — and on a single manufacturer to assemble the mobile console and patient-positioning system, so a supplier/assembler disruption could halt system production.
“We rely on single-source suppliers for some components used in our NeuroStar Advanced Therapy System, and we do not have long-term supply contracts with these suppliers. Furthermore, we rely on a single manufacturer for the assembly of the mobile console and patient positioning system used in our NeuroStar Advanced Therapy System.”
SEC filing →As of 2026
Other disclosures
- Greenbrook acquisition shifted business to clinic-revenue model (real-estate/operating exposure)medium
After acquiring Greenbrook, Neuronetics' US revenue mix shifted to 59% clinic revenue (from 6%), making it directly responsible for operating leased treatment centers — adding real-estate leasing, tenant-improvement and healthcare-operating risks it did not previously bear as a device maker.
“Clinic revenues represented 59% of our U.S. revenues for the year ended December 31, 2025 compared to 6% of our U.S. revenues in the prior year.”
SEC filing →As of 2026
Regulatory & policy
- third-party reimbursement dependence (TMS coverage; Medicaid; Japan) and FDA medical-device regulationlow
Neuronetics depends on TMS reimbursement from federal programs and commercial payors (~95% of US covered lives) and on Japan's government-managed system; Medicaid eligibility restrictions, reimbursement changes, or FDA medical-device requirements could reduce treatment volumes and revenue.
“Many foreign markets, including Japan, have government-managed healthcare systems that govern reimbursement for psychiatric treatments and procedures.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
Teijin Limited
“stribution agreement with Teijin, the Company earned a second milestone payment of $ 0.7 million, following Japan's Central Social Insurance Medical Council (Chuikyo) approval of the recommendation by JMHLW's expert review panel to provide reimbursement for NeuroStar Advanced Therapy for the treatment of MDD in adults.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch